ATE499613T1 - Verfahren zum screening eines arzneistoffs unter verwendung eines 67 kda grossen lamininrezeptors - Google Patents

Verfahren zum screening eines arzneistoffs unter verwendung eines 67 kda grossen lamininrezeptors

Info

Publication number
ATE499613T1
ATE499613T1 AT04725184T AT04725184T ATE499613T1 AT E499613 T1 ATE499613 T1 AT E499613T1 AT 04725184 T AT04725184 T AT 04725184T AT 04725184 T AT04725184 T AT 04725184T AT E499613 T1 ATE499613 T1 AT E499613T1
Authority
AT
Austria
Prior art keywords
effect
drug
inhibiting
laminin receptor
screening
Prior art date
Application number
AT04725184T
Other languages
English (en)
Inventor
Hirofumi Tachibana
Original Assignee
Kyushu Tlo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu Tlo Co Ltd filed Critical Kyushu Tlo Co Ltd
Application granted granted Critical
Publication of ATE499613T1 publication Critical patent/ATE499613T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
AT04725184T 2003-04-01 2004-04-01 Verfahren zum screening eines arzneistoffs unter verwendung eines 67 kda grossen lamininrezeptors ATE499613T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003097652 2003-04-01
PCT/JP2004/004772 WO2004090541A1 (ja) 2003-04-01 2004-04-01 ６７ｋＤａラミニン・レセプターを用いた薬物のスクリーニング方法及びそれにより得られる薬物

Publications (1)

Publication Number Publication Date
ATE499613T1 true ATE499613T1 (de) 2011-03-15

Family

ID=33156647

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04725184T ATE499613T1 (de) 2003-04-01 2004-04-01 Verfahren zum screening eines arzneistoffs unter verwendung eines 67 kda grossen lamininrezeptors

Country Status (10)

Country Link
US (2) US7736856B2 (de)
EP (1) EP1617218B1 (de)
JP (2) JP4572339B2 (de)
KR (1) KR20060005353A (de)
CN (1) CN1798975A (de)
AT (1) ATE499613T1 (de)
AU (1) AU2004227240A1 (de)
CA (1) CA2523186A1 (de)
DE (1) DE602004031517D1 (de)
WO (1) WO2004090541A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008360729A1 (en) * 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
WO2010111671A1 (en) 2009-03-26 2010-09-30 Quantum Immunologics, Inc. Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
JP5797051B2 (ja) * 2011-08-05 2015-10-21 花王株式会社 脂肪細胞の分化成熟抑制剤及び／又は脂肪蓄積抑制剤の探索方法
CN104820059B (zh) * 2015-04-22 2016-07-06 湖南农业大学 一种快速筛选含有EGCG3"Me茶树资源的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565789A (en) * 1983-04-04 1986-01-21 The United States Of America As Represented By The Department Of Health And Human Services Cell matrix receptor system and use in cancer diagnosis and management
ATE130757T1 (de) * 1988-05-20 1995-12-15 Jolla Cancer Res Found Adhäsionsrezeptor für laminin und dessen verwendung.
GB9808407D0 (en) * 1998-04-22 1998-06-17 Univ Belfast Medicament
JP4507027B2 (ja) * 1998-12-04 2010-07-21 明治乳業株式会社 Ｍｍｐ阻害剤
US6410052B1 (en) * 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
JP2001114687A (ja) * 1999-10-13 2001-04-24 Mitsui Norin Co Ltd 抗癌剤
JP4205334B2 (ja) * 2000-11-24 2009-01-07 株式会社 伊藤園 茶に由来する薬理組成物
JP2002200340A (ja) * 2000-12-28 2002-07-16 Sega Corp ゲーム装置，ゲーム方法，およびゲームプログラム
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
AU2004227240A1 (en) 2004-10-21
WO2004090541A1 (ja) 2004-10-21
JPWO2004090541A1 (ja) 2006-07-06
JP2010248201A (ja) 2010-11-04
KR20060005353A (ko) 2006-01-17
US20070021321A1 (en) 2007-01-25
US20100222424A1 (en) 2010-09-02
CN1798975A (zh) 2006-07-05
JP4572339B2 (ja) 2010-11-04
EP1617218A4 (de) 2007-04-25
EP1617218B1 (de) 2011-02-23
US7736856B2 (en) 2010-06-15
DE602004031517D1 (de) 2011-04-07
CA2523186A1 (en) 2004-10-21
EP1617218A1 (de) 2006-01-18

Similar Documents

Publication Publication Date Title
ATE548719T1 (de) Verfahren und vorrichtung zum detektieren einer kritischen situation eines subjekts
DE602004023824D1 (de) Verfahren zum direkten nachweis einzelner methotrexatmetabolite
ATE545168T1 (de) Verfahren zur beurteilung eines internen batterie-kurzschlusses, vorrichtung zur beurteilung eines internen batterie-kurzschlusses, batteriepaket und herstellungsverfahren dafür
EA200802359A1 (ru) Способ определения места по меньшей мере двух воздействий
ATE462350T1 (de) Verfahren und gerät zur laufenden überwachung der konzentration eines analyten
DE602004009716D1 (de) Verwendung von transthyretin als biomarker zum nachweis von kolorektalen adenomen; verfahren und nachweis-system
ATE397098T1 (de) Verfahren zur diagnostik von eierstock endometriose
EP1794318A4 (de) Arzneistoff-screening und molekularer diagnosetest zum frühen nachweis von kolorektalkarzinom: reagentien, verfahren und kits dafür
DE602005018261D1 (de) Verfahren und vorrichtung zum messen von dünnfilmproben
ATE494552T1 (de) Docetaxel-immuntest
DE602005018530D1 (de) Verfahren zum nachweis von mikro-rna-molekülen
DK1664793T3 (da) Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser
ATE499613T1 (de) Verfahren zum screening eines arzneistoffs unter verwendung eines 67 kda grossen lamininrezeptors
DE602006000559D1 (de) Optisches Verfahren und optische Vorrichtung zur Erkennung von Defekten der Oberfläche und der Struktur eines heißen, sich kontinuierlich bewegenden Produkts
ATE462513T1 (de) Verfahren und vorrichtung zum präzisen positionieren einer anzahl zusammenwirkender walz-oder rollenelemente
ATE466937T1 (de) Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs
DE50214120D1 (de) Verfahren und vorrichtung zur getreideanalyse
DE602004005388D1 (de) Vorrichtung und Verfahren zum Messen und Analysieren der Form eines Objekts, sowie entsprechendes Programm
ATE511636T1 (de) Verfahren zum nachweis biologischer organismen mittels raman-streuung
ATE495441T1 (de) Verfahren zum testen endokriner substanz in proben
WO2007113575A3 (en) Reagents and methods for cross-linking biological molecules
FI20040471A0 (fi) Menetelmä ja laite punnitusmittausten tarkkuuden parantamiseksi
DE502005002994D1 (de) Verfahren und Vorrichtung zum Bestimmen der Konzentrationen von mindestens zwei Liganden
ATE432469T1 (de) Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs
EP4399508A4 (de) Vorrichtung zum nachweis von analyten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties